Treatment Adjustment in commonly used Biologics for the treatment of moderate to severe chronic plaque psoriasis: a German real world retrospective study (TABU)

Treatment Adjustment in commonly used Biologics for the treatment of moderate to severe chronic plaque psoriasis: a German real world retrospective study (TABU) - TABU

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017588

Enrollment

1000

Registered

2019-07-04

Start date

2019-07-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis L40

Interventions

Group 1: In this study retrospective and anonymized data on therapy adjustments will be collected once from patient charts. Only patient charts from patients with plaque psoriasis, that have been cont

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adult patients (between 18 and 65 years of age) whose primary indication for biologic therapy was moderate to severe plaque PsO having received a biologic for a minimum of 36 weeks with either Adalimumab, Guselkumab, Ixekizumab, Secukinumab or Ustekinumab. Patients who received the induction doses of the biologic as per local label.

Exclusion criteria

Exclusion criteria: - Patients having participated in interventional clinical trial(s) during the chart review time period - Patients receiving biologics during pregnancy - Patients stopping biologic therapy due to upfront planned surgeries

Design outcomes

Primary

Measure	Time frame
• To assess the time from initiation of a biologic treatment to first treatment adjustment in the overall study population and per biologic. • Time in days from treatment initiation to treatment adjustment (collected as Yes/No answer in the CRF). Since this is a retrospective one time record, no explicit time for the primary endpoint is set.	—

Secondary

Measure	Time frame
• To assess the relative frequency of different treatment adjustments types in the overall study population and per biologic • To assess the duration of different treatment adjustments types in the overall study population and per biologic • To assess the underlying reasons for treatment adjustments in the overall study population and per biologic • To assess the effectiveness of each treatment in the overall study population and per biologic • To assess the patient characteristics in the group of patients with intensified therapy (dose increase, interval shortening or start of an additional therapy) • To assess the influence of office administration vs. home self-administration on treatment adjustments in the overall study population and per biologic	—

Measure

Time frame

• To assess the relative frequency of different treatment adjustments types in the overall study population and per biologic • To assess the duration of different treatment adjustments types in the overall study population and per biologic • To assess the underlying reasons for treatment adjustments in the overall study population and per biologic • To assess the effectiveness of each treatment in the overall study population and per biologic • To assess the patient characteristics in the group of patients with intensified therapy (dose increase, interval shortening or start of an additional therapy) • To assess the influence of office administration vs. home self-administration on treatment adjustments in the overall study population and per biologic

—

Countries

Germany

Contacts

Public ContactSusana Gomis-Kleindienst

AbbVie Deutschland GmbH & Co. KG

susana.gomis-kleindienst@abbvie.com+496111720 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026